1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2016

Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 150 pages

Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2016’, provides an overview of the Teva Pharmaceutical Industries Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Teva Pharmaceutical Industries Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Teva Pharmaceutical Industries Limited
- The report provides overview of Teva Pharmaceutical Industries Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Teva Pharmaceutical Industries Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Teva Pharmaceutical Industries Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Teva Pharmaceutical Industries Limited’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Teva Pharmaceutical Industries Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Teva Pharmaceutical Industries Limited’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Teva Pharmaceutical Industries Limited Snapshot 6
Teva Pharmaceutical Industries Limited Overview 6
Key Information 6
Key Facts 6
Teva Pharmaceutical Industries Limited - Research and Development Overview 7
Key Therapeutic Areas 7
Teva Pharmaceutical Industries Limited - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Combination Treatment Modalities 14
Pipeline Products - Partnered Products 15
Pipeline Products - Out-Licensed Products 17
Teva Pharmaceutical Industries Limited - Pipeline Products Glance 19
Teva Pharmaceutical Industries Limited - Late Stage Pipeline Products 19
Teva Pharmaceutical Industries Limited - Clinical Stage Pipeline Products 22
Teva Pharmaceutical Industries Limited - Early Stage Pipeline Products 24
Teva Pharmaceutical Industries Limited - Unknown Stage Pipeline Products 26
Teva Pharmaceutical Industries Limited - Drug Profiles 27
(fluticasone propionate + salmeterol xinafoate) 27
deutetrabenazine ER 28
hydrocodone bitartrate ER 30
laquinimod sodium 32
reslizumab 35
omacetaxine mepesuccinate 37
(acetaminophen + hydrocodone bitartarate) IR 40
armodafinil 41
beclomethasone dipropionate 43
bendamustine hydrochloride 45
fluticasone propionate 48
rasagiline mesylate 49
TEV-48125 50
funapide 51
pridopidine hydrochloride 52
TV-1380 54
(acetaminophen + oxycodone hydrochloride) IR 55
(fluticasone propionate + salmeterol xinafoate) MDI 56
CEP-37440 57
glatiramer acetate 58
SD-560 60
TEV-48107 61
TEV-90110 62
TEV-90111 63
TEV-90112 64
TEV-90113 65
TV-44664 66
atropine sulfate 67
CEP-11981 68
CEP-28122 69
CEP-33779 70
Drug for Undisclosed Indication 71
NIB-2 72
NP-201 73
NP-202 74
Recombinant Protein to Inhibit IL-17A for Psoriasis 75
Recombinant Protein to Target CD38 for Multiple Myeloma 76
SD-1077 77
Small Molecule 2 to Antagonize 5-HT6 for CNS Disorders 78
Small Molecule to Antagonize NMDA Receptor for Undisclosed Indication 79
Small Molecule to Inhibit CGRP for Migraine 80
Small Molecules to Inhibit DAT for Sleep Disorders 81
(acetaminophen + immediate release opioid 1) 82
(acetaminophen + immediate release opioid 2) 83
AD-3 84
AD-4 85
Fixed Dose Combination 3 for HIV 86
Fixed Dose Combination 4 for HIV 87
Small Molecule 1 to Antagonize 5-HT6 Receptor for CNS Disorders 88
Small Molecule to Inhibit PARP-1 89
Drug for Dependence 90
Drug for Parkinson's Disease 91
risperidone LAI 92
Teva Pharmaceutical Industries Limited - Pipeline Analysis 93
Teva Pharmaceutical Industries Limited - Pipeline Products by Target 93
Teva Pharmaceutical Industries Limited - Pipeline Products by Route of Administration 98
Teva Pharmaceutical Industries Limited - Pipeline Products by Molecule Type 99
Teva Pharmaceutical Industries Limited - Pipeline Products by Mechanism of Action 100
Teva Pharmaceutical Industries Limited - Recent Pipeline Updates 103
Teva Pharmaceutical Industries Limited - Dormant Projects 128
Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products 131
Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products 131
Discontinued Pipeline Product Profiles 131
Teva Pharmaceutical Industries Limited - Company Statement 134
Teva Pharmaceutical Industries Limited - Locations And Subsidiaries 137
Head Office 137
Other Locations and Subsidiaries 137
Appendix 145
Methodology 145
Coverage 145
Secondary Research 145
Primary Research 145
Expert Panel Validation 145
Contact Us 145
Disclaimer 146

List of Tables
Teva Pharmaceutical Industries Limited, Key Information 10
Teva Pharmaceutical Industries Limited, Key Facts 10
Teva Pharmaceutical Industries Limited - Pipeline by Indication, 2016 13
Teva Pharmaceutical Industries Limited - Pipeline by Stage of Development, 2016 16
Teva Pharmaceutical Industries Limited - Monotherapy Products in Pipeline, 2016 17
Teva Pharmaceutical Industries Limited - Combination Treatment Modalities in Pipeline, 2016 18
Teva Pharmaceutical Industries Limited - Partnered Products in Pipeline, 2016 19
Teva Pharmaceutical Industries Limited - Partnered Products/ Combination Treatment Modalities, 2016 20
Teva Pharmaceutical Industries Limited - Out-Licensed Products in Pipeline, 2016 21
Teva Pharmaceutical Industries Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016 22
Teva Pharmaceutical Industries Limited - Pre-Registration, 2016 23
Teva Pharmaceutical Industries Limited - Filing rejected/Withdrawn, 2016 24
Teva Pharmaceutical Industries Limited - Phase III, 2016 25
Teva Pharmaceutical Industries Limited - Phase II, 2016 26
Teva Pharmaceutical Industries Limited - Phase I, 2016 27
Teva Pharmaceutical Industries Limited - Preclinical, 2016 28
Teva Pharmaceutical Industries Limited - Discovery, 2016 29
Teva Pharmaceutical Industries Limited - Unknown, 2016 30
Teva Pharmaceutical Industries Limited - Pipeline by Target, 2016 97
Teva Pharmaceutical Industries Limited - Pipeline by Route of Administration, 2016 102
Teva Pharmaceutical Industries Limited - Pipeline by Molecule Type, 2016 103
Teva Pharmaceutical Industries Limited - Pipeline Products by Mechanism of Action, 2016 104
Teva Pharmaceutical Industries Limited - Recent Pipeline Updates, 2016 107
Teva Pharmaceutical Industries Limited - Dormant Developmental Projects,2016 132
Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products, 2016 135
Teva Pharmaceutical Industries Limited, Other Locations 141
Teva Pharmaceutical Industries Limited, Subsidiaries 142

List of Figures
Teva Pharmaceutical Industries Limited - Pipeline by Top 10 Indication, 2016 12
Teva Pharmaceutical Industries Limited - Pipeline by Stage of Development, 2016 16
Teva Pharmaceutical Industries Limited - Monotherapy Products in Pipeline, 2016 17
Teva Pharmaceutical Industries Limited - Combination Treatment Modalities in Pipeline, 2016 18
Teva Pharmaceutical Industries Limited - Partnered Products in Pipeline, 2016 19
Teva Pharmaceutical Industries Limited - Out-Licensed Products in Pipeline, 2016 21
Teva Pharmaceutical Industries Limited - Pipeline by Top 10 Target, 2016 97
Teva Pharmaceutical Industries Limited - Pipeline by Route of Administration, 2016 102
Teva Pharmaceutical Industries Limited - Pipeline by Molecule Type, 2016 103
Teva Pharmaceutical Industries Limited - Pipeline Products by Top 10 Mechanism of Action, 2016 104

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.